LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 175M 153M 141M 131M 248M 16.72B 252M 1.69B 664M 8.23B 658M 644M 28.31B | P/E 2026 * |
-1.24x | P/E 2027 * | -1.65x |
|---|---|---|---|---|---|
| Enterprise Value | 175M 153M 141M 131M 248M 16.72B 252M 1.69B 664M 8.23B 658M 644M 28.31B | EV / Sales 2026 * |
9.24x | EV / Sales 2027 * | 2.72x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.75% | -4.79% | - | - | 175M | |
| -4.14% | -8.06% | +58.96% | +118.67% | 54.63B | |
| +1.84% | -0.66% | +59.82% | +92.96% | 54.88B | |
| -2.24% | +3.59% | +17.75% | +477.47% | 25.06B | |
| -1.60% | -6.21% | -18.96% | -15.21% | 23.14B | |
| +2.43% | +1.06% | +42.44% | -1.27% | 19.88B | |
| -3.19% | 0.00% | +35.60% | -26.98% | 17.55B | |
| -6.84% | +2.18% | +195.12% | +357.18% | 16.5B | |
| -1.05% | +1.16% | +25.95% | +194.27% | 14.2B | |
| +8.74% | +3.51% | +51.91% | +726.40% | 15.36B | |
| Average | -0.88% | -0.28% | +52.07% | +213.72% | 26.8B | |
| Weighted average by Cap. | -0.91% | -1.46% | +51.26% | +176.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.96M 16.59M 15.3M 14.13M 26.81M 1.81B 27.26M 183M 71.78M 891M 71.19M 69.64M 3.06B | 64.52M 56.44M 52.06M 48.08M 91.23M 6.15B 92.76M 622M 244M 3.03B 242M 237M 10.42B |
| Net income | -141M -124M -114M -105M -200M -13.48B -203M -1.36B -535M -6.64B -531M -519M -22.82B | -109M -95.59M -88.17M -81.44M -155M -10.42B -157M -1.05B -414M -5.13B -410M -401M -17.65B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
